<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138774</url>
  </required_header>
  <id_info>
    <org_study_id>OBEPALIP</org_study_id>
    <nct_id>NCT01138774</nct_id>
  </id_info>
  <brief_title>Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) in Human Obesity</brief_title>
  <acronym>OBEPALIP</acronym>
  <official_title>Cellular and Molecular Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) on Adipose Tissue: Potential Application in Human Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to analyze the effects of Lipoic acid and/or EPA supplementation on
      weight loss, lipid profile, insulin resistance, oxidative and inflammation parameters,
      metabolomic profile as well as on adipose tissue gene profile in healthy overweight/obese
      subjects following an energy-restricted diet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>Week 0 (baseline)</time_frame>
    <description>Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>Week 2</time_frame>
    <description>Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>Week 4</time_frame>
    <description>Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>week 6</time_frame>
    <description>Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>Week 8</time_frame>
    <description>Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body composition and Anthropometric parameters</measure>
    <time_frame>Week 0 (Baseline)</time_frame>
    <description>Changes in body composition will be analyzed by Dual X-ray Absorptiometry (DXA) and by bioimpedance, and hip and waist circumferences will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body composition and anthropometric parameters</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Changes in body composition will be analyzed by Dual X-ray Absorptiometry (DXA) and by bioimpedance, and hip and waist circumferences will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose metabolism parameters</measure>
    <time_frame>Week 0 (baseline)</time_frame>
    <description>Fasting serum glucose, Fasting serum insulin, Oral Glucose Tolerance Test, HOMA index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose metabolism parameters</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Fasting serum glucose, Fasting serum insulin, Oral Glucose Tolerance Test, HOMA index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid metabolism biomarkers</measure>
    <time_frame>Week 0 (baseline)</time_frame>
    <description>Serum total-cholesterol, HDL-cholesterol, LDL-cholesterol, triacylglycerols, free fatty acids, ketone bodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid metabolism biomarkers</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Serum total-cholesterol, HDL-cholesterol, LDL-cholesterol, triacylglycerols, free fatty acids, ketone bodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure and Cardiovascular Risk biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood pressure, PAI-1 and VEGF will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure and Cardiovascular Risk biomarkers</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Blood pressure, PAI-1 and VEGF will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>Baseline</time_frame>
    <description>Energy expenditure will be estimated by indirect calorimetry, and T3, T4 and TSH levels will be analysed by ELISA kits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Energy expenditure will be estimated by indirect calorimetry, and T3, T4 and TSH levels will be analysed by ELISA kits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety</measure>
    <time_frame>Baseline</time_frame>
    <description>Satiety will be estimated by using a VAS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Satiety will be estimated by using a VAS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inflammation biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>TNF-alpha, IL-6, C-reactive protein, serum A-amiloid, Leptin, Adiponectin, Visfatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inflammation biomarkers</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>TNF-alpha, IL-6, C-reactive protein, serum A-amiloid, Leptin, Adiponectin, Visfatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum oxidative stress biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Total and Reduced Glutathione, Glutathione Peroxidase, MDA, Superoxide Dismutase-2 (Mn-SOD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum oxidative stress biomarkers</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Total and Reduced Glutathione, Glutathione Peroxidase, MDA, Superoxide Dismutase-2 (Mn-SOD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue gene profile and function analysis</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>A biopsy (2 g) of subcutaneous abdominal periumbilical area adipose tissue will be obtained. In order to identify clusters/pathways of genes regulated by the supplementation of EPA and LA, microarray gene profiling will be performed in adipose tissue from the 4 groups after the nutritional intervention. If possible primary explant culture of adipose tissue biopsies will be also carried out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic and lipidomic profile</measure>
    <time_frame>Baseline</time_frame>
    <description>Samples of plasma and 24-h urine will be analysed by Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS), and Nuclear Magnetic Resonance (NMR), and Bidimensional Gas Chromatography-Mass Spectrometry (BC-MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic and lipidomic profile</measure>
    <time_frame>Week 10 (end of treatment)</time_frame>
    <description>Samples of plasma and 24-h urine will be analysed by Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS), and Nuclear Magnetic Resonance (NMR), and Bidimensional Gas Chromatography-Mass Spectrometry (BC-MS).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Obesity</condition>
  <condition>Body Fat</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipoic acid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPA+LA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Double blind dietary intervention with EPA and lipoic acid</intervention_name>
    <description>Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>EPA group</arm_group_label>
    <arm_group_label>Lipoic acid group</arm_group_label>
    <arm_group_label>EPA+LA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women

          -  Ages between 20 and 45 years, and with regular menstrual cycles

          -  Body Mass Index (BMI) between 27.5 and 39.9 kg/m2

          -  Weight unchanged (± 3 kg) for the last 3 months

          -  All subjects should have an overall physical and psychological condition that the
             investigator believes is in accordance with the overall aim of the study.

        Exclusion Criteria:

          -  Use of prescription medication

          -  To suffer from any chronic metabolic or obesity related disease, hepatic or renal
             systemic disease: Hypertension, dislipidemia, type 1 or 2 diabetes, thyroid function
             disorders, cirrhosis, fatty liver, etc.

          -  Food allergies or food intolerance expected to come up during the study

          -  Special diets (Atkins, vegetarian, etc.) prior three months the start of the study.

          -  Eating disorders

          -  Surgically treated obesity

          -  Pregnant or lactating women or planning to be pregnant in the next two months

          -  Alcohol or drug abuse (based on clinical parameters)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria J Moreno-Aliaga, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Martínez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santiago Navas-Carretero, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nutrition, Food Science, Physiology and Toxicology. University of Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.unav.es/caft/</url>
    <description>Department of Nutrition, Food Science, Physiology and Toxicology</description>
  </link>
  <link>
    <url>http://www.unav.es/master/nutricion-metabolismo/</url>
    <description>European Master´s Degree in Feeding, Nutrition and Metabolism</description>
  </link>
  <reference>
    <citation>Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Barber A, Martínez JA, Moreno-Aliaga MJ. Lipoic acid prevents body weight gain induced by a high fat diet in rats: effects on intestinal sugar transport. J Physiol Biochem. 2009 Mar;65(1):43-50.</citation>
    <PMID>19588730</PMID>
  </reference>
  <reference>
    <citation>Lorente-Cebrián S, Bustos M, Marti A, Martinez JA, Moreno-Aliaga MJ. Eicosapentaenoic acid up-regulates apelin secretion and gene expression in 3T3-L1 adipocytes. Mol Nutr Food Res. 2010 May;54 Suppl 1:S104-11. doi: 10.1002/mnfr.200900522.</citation>
    <PMID>20352620</PMID>
  </reference>
  <reference>
    <citation>Lorente-Cebrián S, Bustos M, Marti A, Martinez JA, Moreno-Aliaga MJ. Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes. Clin Sci (Lond). 2009 Aug 14;117(6):243-9. doi: 10.1042/CS20090020.</citation>
    <PMID>19296827</PMID>
  </reference>
  <reference>
    <citation>Pérez-Echarri N, Pérez-Matute P, Marcos-Gómez B, Marti A, Martínez JA, Moreno-Aliaga MJ. Down-regulation in muscle and liver lipogenic genes: EPA ethyl ester treatment in lean and overweight (high-fat-fed) rats. J Nutr Biochem. 2009 Sep;20(9):705-14. doi: 10.1016/j.jnutbio.2008.06.013. Epub 2008 Sep 30.</citation>
    <PMID>18829285</PMID>
  </reference>
  <reference>
    <citation>Pérez-Echarri N, Pérez-Matute P, Marcos-Gómez B, Baena MJ, Marti A, Martínez JA, Moreno-Aliaga MJ. Differential inflammatory status in rats susceptible or resistant to diet-induced obesity: effects of EPA ethyl ester treatment. Eur J Nutr. 2008 Oct;47(7):380-6. doi: 10.1007/s00394-008-0738-3. Epub 2008 Sep 18.</citation>
    <PMID>18807107</PMID>
  </reference>
  <reference>
    <citation>Pérez-Echarri N, Pérez-Matute P, Marcos-Gómez B, Martínez JA, Moreno-Aliaga MJ. Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats. Br J Nutr. 2009 Apr;101(7):1059-67. doi: 10.1017/S0007114508048307. Epub 2008 Aug 28.</citation>
    <PMID>18755047</PMID>
  </reference>
  <reference>
    <citation>Pérez-Matute P, Pérez-Echarri N, Martínez JA, Marti A, Moreno-Aliaga MJ. Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-alpha. Br J Nutr. 2007 Feb;97(2):389-98.</citation>
    <PMID>17298710</PMID>
  </reference>
  <reference>
    <citation>Marrades MP, Martínez JA, Moreno-Aliaga MJ. Differences in short-term metabolic responses to a lipid load in lean (resistant) vs obese (susceptible) young male subjects with habitual high-fat consumption. Eur J Clin Nutr. 2007 Feb;61(2):166-74. Epub 2006 Aug 9.</citation>
    <PMID>16900083</PMID>
  </reference>
  <reference>
    <citation>Marrades MP, Milagro FI, Martínez JA, Moreno-Aliaga MJ. Differential expression of aquaporin 7 in adipose tissue of lean and obese high fat consumers. Biochem Biophys Res Commun. 2006 Jan 20;339(3):785-9. Epub 2005 Nov 22.</citation>
    <PMID>16325777</PMID>
  </reference>
  <reference>
    <citation>Ramel A, Martinéz A, Kiely M, Morais G, Bandarra NM, Thorsdottir I. Beneficial effects of long-chain n-3 fatty acids included in an energy-restricted diet on insulin resistance in overweight and obese European young adults. Diabetologia. 2008 Jul;51(7):1261-8. doi: 10.1007/s00125-008-1035-7. Epub 2008 May 20.</citation>
    <PMID>18491071</PMID>
  </reference>
  <reference>
    <citation>Parra D, Ramel A, Bandarra N, Kiely M, Martínez JA, Thorsdottir I. A diet rich in long chain omega-3 fatty acids modulates satiety in overweight and obese volunteers during weight loss. Appetite. 2008 Nov;51(3):676-80. doi: 10.1016/j.appet.2008.06.003. Epub 2008 Jun 14.</citation>
    <PMID>18602429</PMID>
  </reference>
  <reference>
    <citation>Ramel A, Martinez JA, Kiely M, Bandarra NM, Thorsdottir I. Moderate consumption of fatty fish reduces diastolic blood pressure in overweight and obese European young adults during energy restriction. Nutrition. 2010 Feb;26(2):168-74. doi: 10.1016/j.nut.2009.04.002. Epub 2009 May 31.</citation>
    <PMID>19487105</PMID>
  </reference>
  <reference>
    <citation>Navas-Carretero S, Pérez-Granados AM, Schoppen S, Vaquero MP. An oily fish diet increases insulin sensitivity compared to a red meat diet in young iron-deficient women. Br J Nutr. 2009 Aug;102(4):546-53. doi: 10.1017/S0007114509220794. Epub 2009 Feb 12.</citation>
    <PMID>19210857</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Calorie restriction</keyword>
  <keyword>Eicosapentaenoic acid (EPA)</keyword>
  <keyword>Lipoic acid</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Lipid metabolism</keyword>
  <keyword>Adipokines</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Adipose tissue gene profile</keyword>
  <keyword>Metabolomic profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

